Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexicon Pharmaceuticals Inc LXRX

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.


NDAQ:LXRX - Post by User

Bullboard Posts
Post by mart33on Mar 24, 2008 8:04pm
740 Views
Post# 14766076

Loss narrows and uptrend is born

Loss narrows and uptrend is bornLXRX moved above resistance and crossed its 50-day moving average.Next target SPlooks like $3

Lexicon Pharmaceuticals Inc. reported fourth quarter net loss of $12.2 million or $0.09 per share, compared to a net loss of $13.8 million or $0.19 per share in the previous year.

Total revenues for the quarter declined to $13.8 million from $16.1 million in the prior year quarter.

On average, analysts polled by First Call/Thomson Financial expected loss of $0.12 share, while analysts estimated revenues of $10.02 million for the fourth quarter.

For fiscal 2007, net loss was $58.8 million or $0.59 per share, compared to a net loss of $54.3 million or $0.81 per share in the last year.

Total revenues for the year were $50.1 million, down from $72.8 million in the year-ago.

Bullboard Posts